Ticker | Value | Shares | Price | Security | Type | Insider | Title | Return | Flags | Date |
|---|---|---|---|---|---|---|---|---|---|---|
| No transactions found | ||||||||||
Value Fund II Lp Biotechnology currently holds 838,507 shares of GLYCOMIMETICS INC (GLYC), valued at approximately $0. This represents their equity stake as Executive.
Based on SEC Form 4 filings, Value Fund II Lp Biotechnology has been a net buyer of GLYC stock. They have purchased $165.2M and sold $58.1M worth of shares.
Value Fund II Lp Biotechnology's most recent insider trade was on Oct 29, 2024, when they purchased 440,489 shares at $3.65 per share.
Value Fund II Lp Biotechnology serves as Executive at GLYCOMIMETICS INC (GLYC). They have executed 295 insider transactions totaling $223.2M over their tenure at the company.
Value Fund II Lp Biotechnology holds the position of Executive at GLYCOMIMETICS INC, where they are responsible for executive-level decision-making and strategic oversight. They have been associated with the company for 22 years and currently hold a stake valued at $0.
Value Fund II Lp Biotechnology has shown a buying trading pattern, with $165.2M in total purchases and $58.1M in total sales across all transactions. Their most recent activity indicates a tendency to accumulate shares.
The largest transaction by Value Fund II Lp Biotechnology was on Nov 19, 2020, when they purchased $11.7M worth of OLMA shares. This transaction involved 613,918 shares at $19.00 per share.
Value Fund II Lp Biotechnology currently owns 838,507 shares of GLYCOMIMETICS INC (GLYC), with an estimated value of $0. This stake represents their equity holdings accumulated through purchases, awards, and option exercises.
All of Value Fund II Lp Biotechnology's SEC Form 4 insider trading filings are tracked on this page. Each transaction links directly to the official SEC EDGAR filing. Value Fund II Lp Biotechnology has 295 Form 4 filings on record as an insider at GLYCOMIMETICS INC.
Set alerts for Value Fund II Lp Biotechnology and 40,000+ other insiders.